Pharmacokinetics and distribution of a 33P-labeled anti-human immunodeficiency virus oligonucleotide (AR177) after single-and multiple- dose intravenous administration to rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1480-1488

  Wallace, Thomas L ^a   Bazemore, Scott A ^a   Holm, Karsten ^b   Markham, Peter M ^b   Shea, J Paul ^b   Chaudhary, Nilabh ^a   Cossum, Paul A ^a  

^a Antigenics Inc   (United States)

^b TSI Mason Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTEGRASE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; ZINTEVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CORTEX; LIVER; MALE; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; TISSUE DISTRIBUTION; ANIMAL; BLOOD; CHEMISTRY; FECES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; ANTI-HIV AGENTS; BONE MARROW; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; INJECTIONS, INTRAVENOUS; KIDNEY CORTEX; LIVER; MALE; OLIGONUCLEOTIDES; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0030615089     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. AGRAWAL, S., TEMSAMANI, J., GALBRAITH, W. AND TANG, J.: Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28: 7-16, 1995.
2. BISHOP, J. S., GUY-CAFFEY, J. K., OJWANG, J. O., SMITH, S. R., HOGAN, M. E., COSSUM, P. A., RANDO, R. F. AND CHAUDHARY, N.: Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J. Biol. Chem. 271: 5698-5703, 1996.
3. BURKA, L. T., SANDERS, J. M., KOOL, C. P., KIM, Y. C. AND MATHEWS, H. B.: Absorption and metabolism of 5-(4-nitrophenol)-2,4-pentadienal (Spydust). Toxicol. Appl. Pharmacol. 87: 121-126, 1987.
4. CORNISH, K. G., IVERSEN, P., SMITH, L., ARNESON, M. AND BAYEVER, E.: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence anti-sense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3: 239-247, 1993.
5. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267: 1181-1190, 1993.
6. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269: 89-94, 1994.
7. 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharmacol. Ther. 56: 641-646, 1994.
8. GALBRAITH, W. M., HOBSON, W. C., GICLAS, P. C., SCHECHTER, P. J. AND AGRAWAL, S.: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Anti-sense Res. Dev. 4: 201-206, 1994.
9. LANGE, J.: Combination antiretroviral therapy. Drugs 49: suppl. 1, 32-37, 1995.
10. MAZUMDER, A., NEAMATI, N., OJWANG, J. O., SUNDER, S., RANDO, R. F. AND POMMIER, Y.: Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 35: 13762-13771, 1996.
11. OJWANG, J., BUCKHEIT, R. W., POMMIER, Y., MAZUMDER, A., DE VREESE, K., ESTE, J. A., REYMAN, D., PALLANSCH, L. A., LACKMAN-SMITH, C., WALLACE, T. L., DE CLERQ, E., MCGRATH, M. S. AND RANDO, R. F.: T30177, an oligonucleotide stabilized by an intramolecular guanosine-octet, is a potent inhibitor of laboratory strains and clinical isolates of the human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39: 2426-2435, 1995.
12. RANDO, R. F., OJWANG, J., ELBAGGARI, A., REYES, G. R., TINDER. R., MCGRATH, M. S. AND HOGAN, M. E.: Suppression of human immunodeficiency virus activity in vitro by oligonucleotides which form intramolecular tetrads. J. Biol. Chem. 270: 1754-1760, 1995.
13. SCHNITTMAN, S. M. AND FAUCI, A. S.: Human immunodeficiency virus and acquired immunodeficiency syndrome: An update. Adv. Intern. Med. 39: 305-354, 1994.
14. SRINIVASAN, S. K. AND IVERSEN, P.: Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Clin. Lab. Anal. 9: 129-137, 1995.
15. WALLACE, T. L., BAZEMORE, S. A., KORNBRUST, D. AND COSSUM, P. A.: I. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278: 1306-1312, 1996a.
16. WALLACE, T. L., BAZEMORE, S. A., KORNBRUST, D. AND COSSUM, P. A.: II. Repeat dose toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after bolus intravenous administration to cynomolgus monkeys. J. Pharmacol. Exp. Ther. 278: 1313-1317, 1996b.
17. ZHANG, R., DIASIO, R. B., Lu, Z., LIU, T., JIANG, Z., GALBRAITH, W. M. AND AGRAWAL, S.: Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem. Pharmacol. 49: 929-939, 1995a.
18. ZHANG, R., Lu, Z., ZHANG, X., ZHAO, H., DIASIO, R. B., LIU, T., JIANG, Z. AND AGRAWAL, S.: In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate. Clin. Chem. 41: 836-843, 1995b.
19. ZHANG, R., Lu, Z., ZHAO, H., ZHANG, X., DIASIO, R., HABUS, I., JIANG, Z., IYER, R. P., Yu, D. AND AGRAWAL, S.: In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. 50: 545-556, 1995c.
20. ZHANG, R., YAN, J., SHAHINIAS, H., AMIN, G., Lu, Z., LIU, T., SAAG, M. S., JIANG, Z., TEMSAMANI, J., MARTIN, R. R., SCHECHTER, P. J., AGRAWAL, S. AND DIASIO, R. B.: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58: 44-53, 1995d.